ASCO GU 2021 Kidney Cancer

Viewing 1-20 of 38 articles

ASCO GU 2021: The CLEAR Study of Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib and the SWOG 1500 Trial of Sunitinib, Cabozantinib, Crizotinib, and Savolitinib in Advanced Kidney Cancer: Discussion

ASCO GU 2021: MK-6482 in Patients with Patients with Clear Cell Renal Cell Carcinoma: Discussion

ASCO GU 2021: The Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC): Updated Follow-up of a Phase I/II Study

ASCO GU 2021: Phase 3 Trial of Lenvatinib plus Pembrolizumab or Everolimus Versus Sunitinib Monotherapy as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (CLEAR Study)

ASCO GU 2021: Patterns of Progression in Patients Treated with Nivolumab plus Ipilimumab (NIVO+IPI) Versus Sunitinib (SUN) for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214

ASCO GU 2021: Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Radiology “Write This Down” - What Do Nonradiologists Need to Know

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Quality of Life Corner

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Cure the Cancer or Avoid Dialysis? Helping Decide

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Peri-Operative Morbidity and Mortality in a Modern Series of Patients Treated with Cytoreductive Nephrectomy at Five Centers

ASCO GU 2021: Best of the Journals: Renal Cell Carcinoma – Surgery

ASCO GU 2021: Best of the Journals: Renal Cell Carcinoma – Pathology

ASCO GU 2021: Best of Journals: Renal Cell Carcinoma – Medical Oncology

ASCO GU 2021: Outcomes of First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the International mRCC Database Consortium

ASCO GU 2021: Stereotactic Radiotherapy and Pembrolizumab for Oligometastatic Renal Tumors: The RAPPORT Trial

ASCO GU 2021: Angiogenic and T-Effector Subgroups Identified by Gene Expression Profiling and Propensity for PBRM1 and BAP1 Alterations in Clear Cell Renal Cell Carcinoma

ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib

ASCO GU 2021: NAXIVA: A Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumor Thrombus in Clear Cell Renal Cell Cancer with Venous Invasion

ASCO GU 2021: Sarcomatoid Versus Clear Cell RCC: A Comparative Comprehensive Genomic Profiling Study

ASCO GU 2021: Illustration of Temporal Evolution in Patients with mRCC Using Both ctDNA and Tissue-Based Genomic Data

1
2